Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
NBI-1117568
NEUROCRINE BIOSCIENCES INC
Schizophrenia
5 trials -
NBI-1117568, NBI-1117568
NEUROCRINE BIOSCIENCES INC
Schizophrenia, Schizophrenia
1 trial -
NBI-1117568, NBI-1117568, NBI-1117568 Placebo Capsule
NEUROCRINE BIOSCIENCES INC
Schizophrenia
1 trial -
NBI-34060
NEUROCRINE BIOSCIENCES INC
Insomnia
1 trial -
NBI-74788, Crinecerfont placebo for oral capsules
NEUROCRINE BIOSCIENCES INC
Classic Congenital Adrenal Hyperplasia (CAH)
1 trial -
NBI-98854
NEUROCRINE BIOSCIENCES INC
Tardive Dyskinesia
6 trials -
NDV-01 (sustained-release gemcitabine-docetaxel)
RELMADA THERAPEUTICS, INC.
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
1 trial -
NDV-01 (sustained-release gemcitabine-docetaxel)
RELMADA THERAPEUTICS, INC.
Bladder (Urothelial, Transitional Cell) Cancer
2 trials -
NEORAL® Soft Gelatin Capsules 100mg, Methotrexate 2.5 mg Tablets, Zilbrysq 16.6 mg solution for injection in pre-filled syringe, Prednisolone 5mg Tablets, Azathioprine Tablets 50mg Oprisine, Privigen 100 mg/ml solution for infusion, Soliris 300 mg concentrate for solution for infusion, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 50mg, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 10mg, Methotrexate 2.5 mg Tablets, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 25mg, K
Kyverna Therapeutics
Generalized myasthenia gravis
1 trial -
NI-501; emapalumab, NI-501; emapalumab
Swedish Orphan Biovitrum Pty Ltd
Macrophage activation syndrome (MAS) in the context of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult onset Still's disease (AOSD). MAS in the context of pediatric and adult Systemic Lupus Erythematosus (SLE).
1 trial -
NICOPASS 1,5 mg SANS SUCRE MENTHE FRAICHEUR, pastille édulcorée à l'aspartam et à l’acésulfame potassique, V0018 Placebo
Pierre Fabre Medicament
Cessation of smoking
1 trial -
NIFEDIPINE, Placebo of Nifedipine
Pari Pharma GmbH
obstetric_pathological delivery
1 trial -
NILOTINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, NILOTINIB
Novartis Pharmaceuticals
Chronic Myeloid Leukemia
1 trial -
NIO752, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung
Novartis Pharmaceuticals
Participants with Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
1 trial -
NIVOLUMAB, Bemarituzumab, OXALIPLATIN, FOLINIC ACID, Placebo for AMG 552, CAPECITABINE , FLUOROURACIL
Amgen
Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
1 trial -
NIVOLUMAB, GEMCITABINE, TEPMETKO 225 mg film-coated tablets, PACLITAXEL, DOCETAXEL, ATEZOLIZUMAB, BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, PEMETREXED
CERO THERAPEUTICS HOLDINGS, INC.
Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer
1 trial -
NKTR-102
Nektar Therapeutics UK Limited
Locally Recurrent Breast Cancer
1 trial -
NKTR-181 BID tablets
Nektar Therapeutics UK Limited
Low Back Pain
2 trials -
NKTR-214
Bristol-Myers Squibb
Melanoma
1 trial -
NNC0487-0111
Novo Nordisk A/S
Obesity
1 trial -
NNC0487-0111 B 10142, NNC0487-0111 B 10141, Placebo, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10144
NovoThirteen
Overweight or obesity, and knee osteoarthritis
1 trial -
NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10141, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10146, NNC0487-0111 B 10144
NovoThirteen
Obesity
1 trial -
NNC0487-0111 B 10142, Placebo (NNC0487-0111), NNC0487-0111 B 10143, NNC0487-0111 B 10146, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10141
NovoThirteen
HFpEF or HFmrEF and obesity
1 trial -
NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10142, NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141
NovoThirteen
Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources